Clinical Significance Of MDA-7 In Non-Small Cell Lung Cancer

Purpose: By detecting the expression of MDA-7 in the resected tissue of non-small cell lung cancer and benign lung lesion, and in the serum of non-small cell lung cancer patients, benign lung lesion patients and healthy subjects to evaluate its clinical significance in the carcinogesis and diagnosis of non-small cell lung cancer.Methods: Immunohistochemical staining was used to detect the expression of MDA-7 in 90 resected non-small cell lung cancer and 28 benign lung lesion; ELISA was used to detect the expression of MDA-7 in the serum of 135 non-small cell lung cancer patients, 48 benign lung lesion patients and 40 healthy subjects.Results: The expression of MDA-7 was positive in the cytochylema and cell membrane of tumor cells with the light microscopy. The expression rates of MDA-7 in resected non-small cell lung cancer and benign lung lesion were 55.6% and 24.1%, respectively. There was a significant difference between non-small cell lung cancer and benign lung lesion (P＜0.05). In the resected non-small cell lung cancer tissue, the expression rates of MDA-7 was the highest in adenocarcinoma (73.1%) and the lowest in squamous cell carcinoma (21.4%), and there was a significant difference between the adenocarcinoma and squamous cell carcinoma (P＜0.05). The intensity of MDA-7 expression was positively correlated with the cell differentiation and TNM staging. The expression levels of MDA-7 in the serum of non-small cell lung cancer, benign lung lesion and healthy subjects were 100.07±21.35pg/ml, 62.79±8.88pg/ml and 68.36±9.53pg/ml, respectively. The expression levels of MDA-7 in the serum of non-small cell lung cancer were significantly higher than that in the benign lung lesion and the healthy subjects (both P values＜0.001), but There was no significant difference between the benign lung lesion and the healthy subjects (P＞0.05).Conclusions: The expression of MDA-7 in the tissue and serum may be used as a potential clinical tool for the diagnosis and prognosis of non-small cell lung cancer.